Insmed INSM Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| R&D by Product | ||||||
| ARIKAYCE external R&D expenses | $37.94M-35.1% | $41.44M-31.2% | $47.42M-22.0% | $54.57M-9.1% | $58.46M-3.7% | |
| Brensocatib external R&D expenses | $94.34M-5.4% | $96.52M-2.1% | $97.53M-4.1% | $95.47M-14.5% | $99.71M-1.2% | |
| Other external R&D expenses | $134.46M+27.6% | $129.87M+43.3% | $128.6M+45.7% | $118.94M+25.8% | $105.41M-6.5% | |
| TPIP external R&D expenses | $122.39M+99.6% | $94.2M+42.9% | $79.3M+37.4% | $67.18M+25.2% | $61.31M+19.2% | |
| Product revenues, net by Geography | ||||||
| International | $160.82M— | $153.47M— | $144.24M— | $130.49M— | —— | |
| US | $658.74M+151% | $452.95M+77.8% | $302.78M+23.4% | $267.62M+12.6% | $262.73M+13.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Insmed break its business down?
- Insmed (INSM) reports r&d by product across 5 parts — ARIKAYCE external R&D expenses, Brensocatib external R&D expenses, INS1148, Other external R&D expenses and TPIP external R&D expenses. Each is extracted from the segment footnotes and tracked over time.
- Where does Insmed's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Insmed's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
